IL13 and asthma: Lebrikizumab, an MAb to IL-13, improved lung function in a randomized, double-blind, placebo-controlled study of 219 adults who had asthma that was inadequately controlled despite inhaled glucocorticoid therapy (ClinicalTrials.gov number, NCT00930163).55